ORGANIZATION

The International School of Metronomic chemotherapy (ISMe) founded by Marina Elena Cazzaniga, has the aim to improve the knowledge in this particular type of treatment, its characteristic mechanisms of action, the most recent results in different types of cancer, as well as contributing to scientific exchange among physicians, clinicians and basic researchers involved in this field.
By improving the skills of all health professionals dealing with cancer patients, ISMe helps shorten the time needed to transfer knowledge from research centres to daily practice.
Last but not least, is that the School has no charging fees.

MISSION STATEMENT

In 2014, almost one and a third million people died from cancer in the EU-28, which equated to more than one quarter (26.4 %) of the total number of deaths. Cancer accounted for a somewhat higher share (29.7 %) of deaths among men than among women (23.2 %). Data EUROSTAT extracted in September 2017.

In 2018, 3.9 million new cases of cancer (all types, excluding non-melanoma skin cancer) and over 1.9 million cancer deaths are estimated in Europe. Lung, colon, female breast, pancreas and prostate cancers account for nearly half (49%) of all deaths due to cancer
57% of new cancer cases in 2012 occurred in less developed regions of the world that include Central America and parts of Africa and Asia; 65% of cancer deaths also occurred in these regions.
Approximately 38.4% of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013–2015 data).
A recent comprehensive report of the advances in cancer field in the last decade shows that progress has been slow in terms of improved outcomes, quality of life, awareness and information regarding cancer disease. The level of evidence used to base many recommendations remains low, and more and better designed trials are needed to address clinically important questions in different areas of cancer care.

Every advanced cancer patient must have access to optimal cancer treatment and supportive care according to the highest standards of patient-centred care, as defined by:

– Open communication between patients and their cancer care teams as a primary goal.

Educating patients about treatment options and supportive care, through development and dissemination of evidence-based information in a clear, culturally appropriate form.

Encouraging patients to be proactive in their care and to share decision-making with their health care providers.

Empowering patients to develop the capability of improving their own quality of life within their cancer experience.

– Always considering patient preferences, values and needs as essential to optimal cancer care [Cardoso F, 2018].

Metronomic chemotherapy refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged drug-free breaks that leads to antitumor activity [Cazzaniga ME, 2017]. A great number of Phase II studies have been published starting from mid-2000s, showing an increasing interest of clinicians on this topic. The results of these studies showed that this strategy is not only effective but has a low toxicity profile too, proposing as a promising strategy for some cancer patients.

Devoted to patients - Devoted to Knowledge

ISMe’s mission is reflected in its motto “Devoted to patients – Devoted to Knowledge”, which emphasizes on one side the willingness to be close to cancer patients, their needs and their expectations in terms of new possibilities of cure, on the other side the importance of rapidly sharing among colleagues the new results of this treatment protocol.

ISMe’s aim is also to pay particular attention on the development of easy and affordable ways to the transfer of knowledge in geographical areas that are least supported by pharmaceutical companies as well as in Countries and regions with limited economical resources.

Industry Support

As an independent, non-profit organisation which has the mission to improve the knowledge about clinical results and patient opportunities, ISMe is committed to working with all stakeholder groups trying to improve treatment opportunities.

The School recognises that different industries make an important contribution to improve cancer outcomes, through a cultural exchange web-based program. For this reason, ISMe fosters on-going dialogue and collaboration with industry partners, by maintaining at the same time a complete independency from them.

The School maintains total editorial control over the planning and execution of all EUmCHT projects. Partners may be invited to contribute with ideas, as appropriate, but decisions about procedures and content are made by the Faculty.

The current industry partner supports the International School of Metronomic Chemotherapy (ISME),meetings and educational initiatives, in line with ISME’s mission to develop knowledge on metronomic chemotherapy.
Do not hesitate to contact the ISME Administration or School Manager for more information about sponsorship opportunities.
ISME is supported through an unrestricted educational grant from Pierre Fabre Pharma

who we are

President

Marina E Cazzaniga
Director Phase 1 Research Center
ASST Monza
Phone: +39 0392339037
Fax: +39 0392333539 

Marina E Cazzaniga

Scientific Committee


André Nicolas
Department of Hematology & Pediatric Oncology, Hôpital pour Enfants de La Timone, AP-HM and head of the SMARTC CRO2- (Centre de Recherche en Cancérologie de Marseille)
Nicolas.ANDRE@ap-hm.fr
_____
Bocci Guido
Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
guido.bocci@med.unipi.it
_____
Camerini Andrea
Medical Oncology, Versilia Hospital and Istituto Toscano Tumori, Lido di Camaiore, Italy.
andreacamerini@katamail.com
_____
Kerbel Robert
Preclinical translational research, Sunnybrook Health Sciences Centre Toronto,
robert.kerbel@sri.utoronto.ca
_____
Munzone Elisabetta
Division of Medical Senology, European Institute of Oncology, Milan, Italy.
elisabetta.munzone@ieo.it
_____
Shaked Yuval
Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
yshaked@technion.ac.il
_____
Wysocki Piotr
Jagiellonian University – Medical College Hospital, Cracow, Poland
piotr.wysocki@uj.edu.pl

School Secretary’s contacts

Administrative Officer: Laura Ciboldi
School Manager: Monica Perez Gila

Faculty Members

Department of Hematology & Pediatric Oncology,
Hôpital pour Enfants de La Timone, AP-HM and head of the SMARTC CRO2-
(Centre de Recherche en Cancérologie de Marseille)
Nicolas.ANDRE@ap-hm.fr

Professor of Paediatrics at the University of Cologne, Germany
frank.berthold@uk-koeln.de

Laboratory of Hematology-Oncology and Hemo-Lympho Pathology Unit
European Institute of Oncology, Milan, Italy
francesco.bertolini@ieo.it

Division of Pharmacology, Department of Clinical and Experimental Medicine
University of Pisa, Via Roma, 55, I-56126, Pisa, Italy
guido.bocci@med.unipi.it

Medical Oncology, Versilia Hospital and Istituto Toscano Tumori
Lido di Camaiore, Italy
andreacamerini@katamail.com

Department of Medicine and Surgery, University of Milano-Bicocca
Monza, Italy
mariagrazia.cerrito@unimib.it

Assistant-Professor of Pharmacokinetics and Chair the Master Degree of Pharmacokinetics at Aix Marseille University, and La Timone University Hospital of Marseille, France
ciccolini.joseph@gmail.com

King’s College Hospital Trust,
London UK
chrisscox@gmail.com

Medical Oncologist Scientist, Odette Cnacer Centre
Sunnybrook Healt Sciensec Centre, Toronto
urbam.emmenegger@sri.utoronto.ca

Direttore di Unitò Operativa Complessa – Policlinico di Milano
francesco.grossi@policlinico.mi.it

Preclinical translational research,
Sunnybrook Health Sciences Centre
Toronto
robert.kerbel@sri.utoronto.ca

Department of Oncology, Jagiellonian University-Medical College
Cracow, Poland
lukasz.kwinta@uj.edu.pl

Division of Medical Senology, European Institute of Oncology
Milan, Italy.
emilia.montagna@ieo.it

Division of Medical Senology, European Institute of Oncology
Milan, Italy
elisabetta.munzone@ieo.it

Anticancer Fund
Brussels, Belgium
pan.pantziarka@anticancerfund.org

Permanent CNSR researcher, Institut national de la santé et de la recherche médicale (INSERM)
eddy.pasquier@inserm.fr

University of Graz
Graz, Austria
edgar.petru@medunigraz.at

Department of Oncology, Jagiellonian University-Medical College
Cracow, Poland
pawel.potocki@uj.edu.pl

Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo
Castellanza, Italy
urestelli@gmail.com

Oncology Service, Jaen City Hospital
Jaén, Spain
oncopsr@yahoo.es

Professor at the Department of cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel
yshaked@tx.technion.ac.il

Nursing Sister – ABJ Benoni Oncology Practice
Benoni, Gauteng
loureins@oncology-sa.co.za

Department of Pediatric Oncology, University of Brno, Czech Republic
sterba.jaroslav@fnbrno.cz

Division of Medical Oncology, Department of Internal Medicine, Yeouido St. Mary’s Hospital
College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
insookwoo@catholic.ac.kr

Department of Oncology, Jagiellonian University – Medical College Hospital
Krakow, Poland
piotr.wysocki@uj.edu.pl

South East Asian Faculty Members

Copeman Clinic, Palm Beach, NSW (AUSTRALIA)

mcopeman@bigpond.net.au

Peking Union Medical College Hospital, Bejing (CHINA)

13910217780@139.com

Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital (CHINA)

hezhiyong@fjzlhospital.com

Cancer Institute head of Philippine General Hospital, Manila (PHILIPPINES)

spikeignacio@gmail.com

Catholic University of Korea, Seoul (South Korea)

insookwoo@catholic.ac.kr

Vice Director of Cho Ray Cancer Center (VIETNAM)

ltadr@yahoo.com

Division of Medical Oncology, National Cancer Centre Singapore

elaine.lim.hsuen@singhealth.com.sg

Nuclear Medicine and Oncology Center Bach Mai Hospital, Ha Noi (Vietnam)

khoa.maitrong@gmail.com
khoa.maitrong@yahoo.com

National Cancer Centre Singapore

ng.quan.sing@singhealth.com.sg

Changzheng Hospital Cancer Research, Shanghai (CHINA)

Jiejunw19@163.com

Chief Physician, MD, PhD,Department of Medical Oncology, Cancer Center,Sun Yat-sen University – Guangzhou  (China)

wangshs@sysucc.org.cn